Jacobs Levy Equity Management Inc. Purchases Shares of 244,245 Tyra Biosciences, Inc. (NASDAQ:TYRA)

Jacobs Levy Equity Management Inc. purchased a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 244,245 shares of the company’s stock, valued at approximately $3,395,000. Jacobs Levy Equity Management Inc. owned 0.48% of Tyra Biosciences at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Janus Henderson Group PLC lifted its stake in shares of Tyra Biosciences by 63.6% in the fourth quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company’s stock valued at $24,291,000 after buying an additional 679,124 shares during the period. Farallon Capital Management LLC bought a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $13,914,000. Deutsche Bank AG lifted its stake in shares of Tyra Biosciences by 52.0% in the fourth quarter. Deutsche Bank AG now owns 18,909 shares of the company’s stock valued at $263,000 after buying an additional 6,466 shares during the period. Cubist Systematic Strategies LLC bought a new stake in shares of Tyra Biosciences in the fourth quarter valued at about $1,526,000. Finally, Bank of America Corp DE lifted its stake in shares of Tyra Biosciences by 21.7% in the fourth quarter. Bank of America Corp DE now owns 66,157 shares of the company’s stock valued at $920,000 after buying an additional 11,804 shares during the period. 84.14% of the stock is currently owned by institutional investors.

Tyra Biosciences Stock Down 3.1%

NASDAQ:TYRA opened at $9.67 on Thursday. Tyra Biosciences, Inc. has a 12-month low of $6.42 and a 12-month high of $29.60. The firm has a market capitalization of $513.38 million, a PE ratio of -6.01 and a beta of 1.17. The firm has a 50-day moving average price of $9.58 and a 200 day moving average price of $12.97.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.02. On average, research analysts expect that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TYRA. Wedbush reiterated an “outperform” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Friday, March 28th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Tyra Biosciences in a research note on Monday, March 31st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.